[{"id":"7246a629-768b-4557-b16c-b951baaa4ed1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03742258","created_at":"2021-01-18T18:19:49.340Z","updated_at":"2025-02-25T15:34:14.094Z","phase":"Phase 1","brief_title":"Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT03742258","lead_sponsor":"Northwestern University","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC overexpression • MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • mivavotinib (CB-659) • Riabni (rituximab-arrx) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 03/12/2021","primary_completion_date":" 03/12/2021","study_txt":" Completion: 12/19/2028","study_completion_date":" 12/19/2028","last_update_posted":"2025-02-11"},{"id":"3bafa6d0-29f9-4e0c-8308-7ec0cbbe6ef5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03010358","created_at":"2021-01-18T14:49:09.492Z","updated_at":"2024-07-02T16:35:40.703Z","phase":"Phase 1/2","brief_title":"Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03010358","lead_sponsor":"Alexey Danilov, MD","biomarkers":" CCND1 • FCER2","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression","tags":["CCND1 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • entospletinib (GS-9973)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 07/17/2017","start_date":" 07/17/2017","primary_txt":" Primary completion: 04/29/2021","primary_completion_date":" 04/29/2021","study_txt":" Completion: 04/29/2021","study_completion_date":" 04/29/2021","last_update_posted":"2023-08-08"},{"id":"d384b94e-6fc8-48b6-bbe8-626e4e7ac7cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT01994382","created_at":"2021-01-18T09:05:54.582Z","updated_at":"2024-07-02T16:36:14.056Z","phase":"Phase 1/2","brief_title":"Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL","source_id_and_acronym":"NCT01994382","lead_sponsor":"Alexion Pharmaceuticals","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Truxima (rituximab-abbs) • cerdulatinib (ALXN2075)"],"overall_status":"Completed","enrollment":" Enrollment 260","initiation":"Initiation: 08/30/2013","start_date":" 08/30/2013","primary_txt":" Primary completion: 12/15/2020","primary_completion_date":" 12/15/2020","study_txt":" Completion: 12/15/2020","study_completion_date":" 12/15/2020","last_update_posted":"2022-04-05"},{"id":"e1835066-cc40-486d-a9fc-79eab09f9dbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04057118","created_at":"2021-01-18T19:53:25.645Z","updated_at":"2024-07-02T16:36:40.129Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.","source_id_and_acronym":"NCT04057118","lead_sponsor":"Oscotec Inc.","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"],"overall_status":"Unknown status","enrollment":" Enrollment 148","initiation":"Initiation: 03/20/2019","start_date":" 03/20/2019","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2020-10-12"}]